Evaluating the Commercial Pathway of Emerging Cardiac Patch Technology by France, Gabrielle et al.
Worcester Polytechnic Institute
Digital WPI
Major Qualifying Projects (All Years) Major Qualifying Projects
February 2018
Evaluating the Commercial Pathway of Emerging
Cardiac Patch Technology
Gabrielle France
Worcester Polytechnic Institute
Morgan L. Maiola
Worcester Polytechnic Institute
Rachael M. Lanni
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/mqp-all
This Unrestricted is brought to you for free and open access by the Major Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Major Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
France, G., Maiola, M. L., & Lanni, R. M. (2018). Evaluating the Commercial Pathway of Emerging Cardiac Patch Technology. Retrieved
from https://digitalcommons.wpi.edu/mqp-all/2675
Project Number: WTT ABC1 
  
Evaluating the Commercial Pathway of Emerging Cardiac Patch 
Technology 
  
A Major Qualifying Project 
Submitted to the Faculty 
of 
WORCESTER POLYTECHNIC INSTITUTE 
in partial fulfillment of the requirements for the 
Degree of Bachelor of Science 
in Management Engineering, Biomedical Engineering Concentration 
  
By: 
Gabrielle France 
Rachael Lanni 
Morgan Maiola 
  
Date: 
02 March 2018 
  
Report Submitted to: 
  
Professor Walter Towner, PhD, MBA, Advisor 
Professor Helen Vassallo, PhD, MBA, Co-Advisor 
Professor George Pins, PhD, Sponsor 
Worcester Polytechnic Institute 
  
  
2 
 
Abstract 
The overall objective of this research was to evaluate the commercial pathway of 
emerging cardiac patch technology. Our review of the state of the art indicated that the current 
cardiovascular patch market would benefit from a cardiac patch that promotes regeneration of 
myocardial tissue as well as prompts both mechanical and electrical properties. The approach 
presented relies on the decomposition of the functional elements of determining the commercial 
pathway, which includes (1) determining the customer applicability for the cardiac patch user, 
(2) evaluating the current cardiac patch competitive landscape, and (3) determining the best go-
to-market strategy for generating income. Methods used included: performing external research 
on the biomedical engineering device market as well as conducting interviews with professionals 
in the industry. The results gathered from our research show the value proposition of the cardiac 
patch technology in the market. The information and research gathered allowed the project team 
to draw a conclusion on the commercial pathway of the cardiac patch, and determine the 
business model that best fits the market. 
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Chapter 1: Introduction 
Nearly 800,000 Americans have a heart attack every year, which is equal to one attack 
every 40 seconds (Benjamin, 2017). Coronary artery disease is the leading cause of myocardial 
infarctions, or heart attacks, as high plaque buildup in arteries can lead to a blockage or rupture 
in the heart. Heart attacks increase a person’s chance of heart failure, abnormal heart rhythms, 
sudden cardiac arrest, damaged organ function throughout the body, or even death 
(“Understanding Heart Attack,” 2017). Despite the fact that heart attacks have become 
increasingly common, there remain little treatment options for those afflicted. Cardiac 
transplantation surgery is one treatment, but has a 99% mortality rate (Pins, Personal 
Communication, 2017).  
In recent years, cardiac patches have gained popularity by attempting to replace damaged 
or scarred heart tissue. The structure of a cardiac patch combines cell therapies and 
bioengineered scaffolding to try to encourage myocardial tissue regeneration. However, current 
cardiac patches on the market are deeply limited in functional ability, as most are made of 
synthetic materials that lack the mechanical and electrical properties of the heart. Therefore, 
there remains a significant unmet need to develop a cardiac patch with integrated contractile 
properties for proper myocardial regeneration (Pins, Personal Communication, 2017). 
Professors George Pins and Glenn Gaudette of Worcester Polytechnic Institute have 
developed a composite cardiac patch made up of layers of microthread-based composite 
scaffolds and rat cells. The goal of the cardiac patch as bioengineered myocardium is to replace a 
piece of damaged heart tissue with a patch that has the same properties as real cardiac tissue. 
With strong progress in the development of the cardiac patch, this project, in conjunction with 
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the WPI Foisie Business School and Biomedical Engineering Department, sought the best 
method for commercializing this technology.  
1.1 Problem Statement 
The overall problem that this Major Qualifying Project addressed was evaluating the 
commercial pathway of emerging cardiac patch technology developed at WPI. 
1.2 Project Objectives 
The project team sought to complete three main objectives, namely, 
1. Determining customer applicability for the cardiac patch user 
2. Evaluating the current cardiac patch market 
3. Determining the best go-to-market strategy for generating income  
Each of these objectives and overall goal were summarized using Axiomatic Design, an 
engineering design tool, outlined in Chapter 2. 
1.3 Project Scope and Deliverables 
The focus of this MQP was to evaluate the commercial pathway of emerging cardiac 
patch technology developed on-campus at WPI. It is important to note that the cardiac patch was 
still early in its development stage at the time of this MQP. As the biomedical engineering team 
continues with its development, clinical trials, and gaining FDA approval, the best 
commercialization route may change in order to best fit the needs of the product and team. This 
project analyzed customer need, the cardiac patch market, and three business model routes in 
order to determine whether the cardiac patch was worth commercializing. The deliverables for 
this MQP included: 
- An analysis of the current cardiac patch market and potential demand 
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- A comparison of licensing, acquisition, and start-up commercialization options 
- Recommended geographic locations for initial market entry  
- Recommended best go-to-market route of commercialization at this stage of development 
- A cost-benefit analysis for use throughout the future development process 
- An Excel sheet with detailed financials   
- A situation analysis using traditional business tools including:  
o SWOT Analysis: Strengths, weaknesses, opportunities, and threats 
o 5 C’s Analysis: Company, customers, competitors, collaborators, and context  
1.4 Project Timeline 
The MQP began on August 24th, 2017 and ended on March 2nd, 2018. The Gantt chart in 
Appendix E shows a detailed outline of each of the project steps throughout the 21-week 
timeline.   
 
 
 
 
 
 
 
 
 
 
 
13 
 
Chapter 2: Methodology 
The methodology was broken down into categories that are related to the project timeline. 
1) Week 1-7: Determining the Problem 
a) Axiomatic Design and Acclaro 
2) Week 8-14: Information Acquisition 
a) Research 
i) Medical literature on various types of infarcts, medical devices 
ii) Research on intellectual property and patents for medical devices 
b) Contacts 
i) Medical device companies 
ii) Medical device consulting firms  
iii) WPI professors, staff, alumni 
3)  Week 15-21: Analyses 
a) Cost-Benefit Analysis 
b) Results and Recommendations 
The information gathered from performing these methods was used to further determine the 
marketability of the cardiac patch. In-depth analyses of this data were conducted to use this 
information to create educated recommendations for the cardiac patch development team.  
2.1 Week 1-7 Approach: Determining the Problem 
 The approach taken for the beginning weeks of the project was broken down into the 
following steps: 
1. Master the functions of Acclaro and Axiomatic Design 
2. Determine the problem that needs to be solved 
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3. Research potential competitors of the cardiac patch  
4. Acquire information on industry standards for commercialization  
Axiomatic design was developed by Nam Suh as an engineering design tool, to help 
engineers pick out a “good” design structure in the most efficient manner possible. A “good” 
design is one that solves a problem in the simplest and easiest way. Axiomatic design teaches 
users how to create the most appropriate system solutions and improvements for the most 
effective outcomes. Essentially, axiomatic design facilitates a better, faster, and cheaper 
approach to engineering design as a whole (Brown, 2013). The design technique has two guiding 
axioms: 
Axiom 1: Maximize independence 
Axiom 2: Minimize information content 
Maximizing the independence of functional requirements for a design allows the engineer to 
change design elements without affecting the other design requirements. Minimizing the 
information content provides for a robust design with the highest probability of successfully 
fulfilling the goals of the design. Together, these two axioms allow for objective evaluations of 
the various possible designs at hand. 
Functional requirements are those pieces of the design required to complete the problem 
at hand. The top-level functional requirement, also known as FR0, is the overarching goal of the 
design and project. Each of the project’s three main objectives are additional functional 
requirements, displayed as subsets or children of FR0. These subset children should add up 
together to equal the main functional requirement, FR0. For example, if a design requires three 
functional requirements to complete FR0, then the following must be true: 
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FR0 = FR1 + FR2 + FR3 
In addition to functional requirements, axiomatic design requires that there also be design 
parameters. Each functional requirement is paired with a single design parameter. These design 
parameters outline the action taken to complete the requirements, using systems or tools. 
Using the software application Acclaro, the project team was able to decompose the MQP 
problem using axiomatic design (Axiomatic Design Solutions, Inc., 2012). Figure 1 displays the 
functional requirements and corresponding design parameters for this MQP. 
 
Figure 1: Acclaro Axiomatic Design Decomposition 
  
Axiom two is satisfied with the above functional requirements being collectively 
exhaustive. In other words, the team and advisors agreed that these functional requirements 
exhaust all those required to evaluate the commercial pathway of the emerging cardiac patch 
technology. Analyzing customer applicability, evaluating the current cardiac patch market and 
competitors, and comparing go-to-market strategies addressed the project team's goal. Axiom 
one is satisfied with the above functional requirements being mutually exclusive. This is 
confirmed by the independence matrix produced by Acclaro during the FR-DP decomposition. 
Since the matrix indicates that all FR-DP pairs are uncoupled, the team is able to change one 
design requirement without affecting the others. This also signals that the requirements were in 
the correct order of which they must be completed for the successful completion of FR0, as 
indicated by the coupling matrix in Table 1.  
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  DP0 DP1 DP2 DP3 
FR0 X O O O 
FR1 O X O O 
FR2 O O X O 
FR3 O O O X 
  
Table 1: Top Level Design Coupling Matrix 
2.2 Week 8-14 Approach: Information Acquisition 
The acquisition of information and data took a number of forms, namely: 
1. Cold calls to medical device companies 
2. Contacting medical device consulting firms 
3. Networking with various WPI professors and staff 
The team’s first method to gain information on medical device commercialization was to 
reach out to medical device companies directly. The calls returned resulted in direction through 
the company’s website, product profiles, and the general consensus that each company had its 
own method for commercializing new products. As a second method, the team then reached out 
to medical device consulting firms, since the team’s position between companies and the patch 
developers was much like that of a medical device consulting firm. Inquiries with a number of 
commercialization firms across the country led to various educational videos and lectures on 
commercializing medical devices. The team discovered, through this outlet, the three major go-
to-market commercialization routes of licensing, acquiring, and building a start-up. 
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The team’s third method of information acquisition consisted of reaching out to contacts 
within the WPI network. Professor Pins’ past and present biomedical engineering PhD students 
provided details on the technological aspects and cost structure of the cardiac patch materials. 
The team also reached out to Yael Schwartz, WPI’s entrepreneur-in-residence, Attorney Robert 
Lombardi, adjunct teaching professor at WPI, and Laura Robinson, WPI’s lead research librarian 
for insight within their respective professional backgrounds.   
Additionally, personal connections through LinkedIn led the team to further resources 
and contacts, including: 
- Commercialization experts (of any product) 
- Commercialization experts (of medical devices) 
- Business development of laboratories 
- Product development experts (of medical devices) 
- Law firms  
- WPI alumni in the medical device industry 
- Online research 
Any information obtained from the stated sources is referred to using in-text citations. 
2.3 Week 15-21 Approach: Analyses 
With the problem defined and information acquired, the project team determined benefits 
and costs of commercialization, as well as accomplished the goal of recommending the best 
route of commercialization to the cardiac patch development team in the final seven weeks of the 
project. In order to do so, the team: 
 Analyzed medical technology Harvard Business School cases 
 Determined value-added benefits of the patch 
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 Calculated patch material and indirect costs 
 Recommended the best go-to-market route 
 Established next steps for the cardiac patch development team 
The project team first analyzed several Harvard Business School cases, including the case 
titled, “Tengion: Bringing Regenerative Medicine to Life,” which outlined the situation of 
competing products within a single company pipeline (Ofek, 2014). With these cases, the project 
team was able to establish the foundation for calculating possible benefits from the 
commercialization of the cardiac patch. The two calculations used to measure added value from 
new medical devices included 1) savings from reduced post-operative complications and 2) 
increase in patients' quality of life. The project team outlined how these calculations can be used 
by the biomedical development team in order to measure the value of the cardiac patch.  
The project team also allocated indirect costs on a per patch basis. Indirect costs included 
the total cost of the regulatory process from the FDA for a Class III medical device and the cost 
of securing proper intellectual property. The team also reached out to UMASS Medical School's 
Office of Technology Transfer for guidance on forming recommendations and next steps for the 
commercialization of the cardiac patch. 
With the methods outlined above, the project team recommended the best go-to-market 
route for commercialization of the cardiac patch at this stage of development and provided 
Professor Pins and the development team with next steps for commercialization.  
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Chapter 3: Results 
The project team concluded that the cardiac patch could successfully be commercialized 
given the following criteria:  
1.     There exists an unmet customer need. 
2.     There exists a market for the product, with healthy competition and positive growth. 
3.     There exists three medical technology business models for profiting from the 
commercialization process of the cardiac patch. 
The following sections provide more detail on each of the three criteria above, including a 
comparison of the advantages and disadvantages of licensing, acquisition, and start-up medical 
technology business models for commercialization of the cardiac patch. This chapter also 
outlines the cost of patch materials and indirect costs, such as FDA approval and securing 
intellectual property rights, as well as the value-added benefits to patients and the cardiac patch 
development team through successful commercialization. 
3.1 Value Proposition 
3.1.1 Unmet Customer Need 
         Every year, 790,000 Americans suffer from a myocardial infarct, more commonly known 
as a heart attack. Of those nearly 800,000 people, 73% experience their first heart attack, while 
27% have a repeat occurrence (Benjamin, 2017). With 86% surviving, this leaves nearly 680,000 
patients now seeking regular cardiac medical care (Mozaffarian, 2017). These patients seeking 
regular cardiac medical care, after surviving a heart attack, would make up the potential market 
demand of those who could benefit from a cardiac patch.   
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Figure 2: Annual Heart Attack Survival Rate, U.S.  
         Damaged myocardium is one the leading causes of heart failure in patients, although 
there are few options for fixing or replacing the damaged heart tissue (Ertl, 2005). One treatment 
for patients whose heart failure has become serious since their heart attack is that of a heart 
transplant. About 2,000 heart transplants are performed each year in the United States, but the 
treatment greatly lacks available donors who are able to provide hearts. Additionally, the median 
survival rate of patients receiving a heart transplant is only about nine years (Everly, 2008). 
         Cardiac patches provide a treatment option for those patients suffering from a heart 
attack, to slow or avoid heart failure. Following the heart attack, a patient can receive a cardiac 
patch which works to replace the damaged heart tissue and restore regular cardiac tissue 
properties and functions. The cardiac patch avoids the need for a heart transplant. Therefore, 
there is still a clear, unmet need for improved cardiac patches.  
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3.1.2 Market Evaluation 
The markets for heart attack treatments and cardiac patches both have positive growth 
outlooks over the next five years. As of 2016, the market for myocardial infarction treatment was 
valued at more than $1.2 billion. That number is expected to grow annually at a rate of just over 
6% to $1.7 billion by 2022, according to a recent study conducted by Zion Market Research 
(Zion Market Research, 2017). Specifically, the market for cardiac and soft tissue repair patches, 
valued at $2.5 billion in 2014, is set to grow at an annual rate of 111% to $5.8 billion by 2022, 
according to a study by Grand View Research (Grand View Research, 2016). 
 
Figure 3: Projected Growth of Markets for the Cardiac Patch 
The United States is expected to be one of the fastest growing regional markets between 
2012 and 2022, due to the developed healthcare infrastructure. Additionally, there are high 
awareness levels about the availability of new technology and solutions invented to solve the 
pre-existing coronary artery disease problem. Thus, in this region, there is a higher usage of 
cardiac patches, creating a market with healthy competition and room to compete. 
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3.2 Medtech Business Model Comparisons 
Each of the three go-to-market business models including licensing, acquisition, and 
start-ups, offers unique advantages and some disadvantages, pertaining to profiting from the 
commercialization of the cardiac patch.  
3.2.1 Licensing 
Licensing is a method of commercialization which grants another business or entity, 
termed the “licensee,” rights to use the product or associated technology from the intellectual 
property of another, termed the “licensor.” The licensor can license certain parts of their 
intellectual property, limiting the licensee’s use to one specific industry, in order to license to 
additional entities as well. Another option for the licensor is to license all of their intellectual 
property in its entirety, in order to allow the licensee to manufacture and sell a prototype of their 
developed product. In either instance, the licensor keeps ownership of their intellectual property. 
All terms of a licensing deal are outlined in a contract negotiated by the licensor and licensee.  
Licensing has many advantages for those inventors looking to commercialize their ideas, 
intellectual property, or prototypes. According to Cayenne Consulting, the most notable 
advantage is that of the financial risk that is mitigated from licensing. The inventor is not 
responsible for funding, manufacturing costs, or other risks and costs associated with running a 
business (Hirai, 2001). Each of these is left to the discretion and responsibility of the licensee. 
Without the need for running one’s own company, the inventor has time to continue researching 
and essentially "makes money while they sleep" by collecting royalties of up to 5%. In the case 
of the cardiac patch, another advantage is that of support from a university setting, including the 
associated Office of Technology Transfer (Davidov, 2013). This office is usually responsible for 
negotiating contract and licensing terms with inventions from the university campus. A UMASS 
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Medical, Worcester licensing officer notes that this advantage allows the inventor to decide 
themselves how involved they become with the legal and negotiating matters of the process (Dr. 
Rawat, Personal Communication, January 30, 2018).  
The largest disadvantage of licensing is that of increased control given up to the licensee. 
Since the licensee is potentially responsible for use of the intellectual property, manufacturing 
the product, and making sales, the licensor depends on the licensee for proper usage of their 
invention. As Dr. Rawat described, “the last thing an inventor wants is for a licensee to simply 
shelf their idea or product” (Personal Communication, January 30, 2018). In addition, licensing 
fees and royalty payments have a smaller upside potential for generated income to the inventor. 
This is true because since the licensee is taking on the most risk, they will likely see more reward 
than that of the licensor.  
3.2.2 Acquisition 
Acquisition is another commercialization method in which larger, well-established 
companies look to acquire single products that are backed by very strong intellectual property 
positions. Medical device consultants confirm that acquisitions most successfully occur with 
products that are synergistic to a company’s overall strategy and can compete in “hot” markets at 
the time (Wodlinger, 2018). Usually a product has already been developed, granted FDA 
approval, and reached some level of sales for acquisition interests to be triggered. However, one-
sixth of medtech acquisitions do still occur when a company is pre-revenue (Hirsch, 2013). With 
high upside potential for generating income and increased control over the product trajectory, the 
acquisition model is promising for further developed ideas (Wodlinger, 2018). 
The acquisition business model for commercialization includes a number of advantages 
for the inventor. The monetary benefit is the most pronounced with a very large upside potential 
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for generating income and making a large sum of money at once. Planning for an acquisition also 
allows an inventor to take control of their idea or intellectual property and bring it to the market 
as they see fit. In other words, control is in the owner’s hands throughout the entire process. This 
changes only when the product is actually acquired, and then the company decides the owner’s 
ongoing role (Wodlinger, 2018). 
Disadvantages of an acquisition-based commercialization model are mainly focused 
around the significant time, capital requirements, and risks that are necessary before benefits are 
acknowledged. Only 25% of medtech acquisitions occur within six years of a company starting 
out, while most require millions of dollars in venture capital and revenue before being acquired. 
For example, OptiMedica raised over $100 million in venture capital, before being acquired by 
Abbott. Similarly, Salient Surgical had to raise nearly $130 million in venture capital and 
produced over $100 million in annual revenues before being acquired by Medtronic (Hirsch, 
2013). The inventor also has the added responsibility of managing normal business functions 
such as manufacturing and sales, as well as any further development and FDA safety testing as 
the product is sold. Once an acquisition occurs, the inventor or owner loses this managerial 
control, as the company brings in its own staff to facilitate the adoption of the new product into 
their business (Wodlinger, 2018). Most importantly, there is no guarantee that an idea or product 
will be acquired. Therefore, an owner must be sure of their position in the market and the 
potential of the idea for interest by a company, before the time and resources are spent.  
3.2.3 Independent Start-Up 
Beginning a start-up company to manufacture, advertise, and sell an idea or product is a 
commercialization method that provides the greatest freedom for an inventor or development 
team. According to medical technology device consultants, Class I and II devices are best to use 
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for creating a start-up, as Class III devices are typically too difficult to fund with this model. 
Class III devices require far more capital than could be withstood by an independent start-up, 
especially as the FDA regulatory process can be lengthy. Inventors need to surround themselves 
with experts in each part of a business, from legal and medical device sales, to manufacturing 
personnel and accountants. Complete control and long-term wealth accompany start-ups, as well 
as a high level of risk (Wodlinger, 2018). 
Start-ups offer the inventor the ability to keep control of their product and technology, the 
intellectual property, and the route of their business. Start-ups allow the inventor to maintain 
ownership, unlike acquisitions which transfer this ownership to the acquiring company. On the 
other hand, start-ups have many disadvantages. The most concerning aspect of the start-up 
commercialization path is the need for large amounts of capital and cash. During the first year, 
the start-up may require tens of thousands of dollars per month, but this can increase 
dramatically as the entity ages (Hirsch, 2013). Owners and developers must also be dedicated to 
the start-up for a long life cycle. Hirsch notes that medical device start-ups time-to-exit take, on 
average, nearly nine years and by then the company will have spent upwards of $50 million 
(2013). 
3.2.4 Scaling Matrix 
The project team developed a weighted scaling matrix in order to compare the three 
medical technology business model options for commercialization. This scale was decided on 
based on consulting research as well as how applicable it was to the cardiac patch. Licensing 
scored a weighted total of 65, with 87% applicability to the project goal and commercialization 
needs. Building an acquisition company scored a weighted total of 41, with 55% applicability to 
the project goal and commercialization needs. Building an independent start-up company scored 
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a weighted total of 34, with 45% applicability to the project goal and commercialization needs. 
The full scaling matrix can be found below in Figure 4 and Appendix A.  
 
Figure 4: Number Ranking Matrix to Determine Route to Commercialization 
For a better representation of this matrix, the team changed the numbers into a color 
scale, with green being “complete applicability to Dr. Pins’ commercialization” and red being 
“no applicability.” This matrix can be seen below in Figure 5, as well as Appendix B. 
 
Figure 5: Color Ranking Matrix to Determine Route to Commercialization 
Through the use of the scaling matrix and scoring system, the team found that the best 
go-to-market strategy for the cardiac patch was licensing with the highest score of the three 
options. The components of each type of company that were developed as a combination of 
insight from Medical Device Consultant Dr. Harold Wodlinger and additional components, the 
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team found through a combination of independent research and Professor Pins’ desires for the 
future of this product. Specifically, the team referred to Dr. Wodlinger’s lecture at Sunnybrook 
Hospital titled “Business Models Fundamentals in Medtech” to gain insight from an industry 
expert on the considerations taken when choosing the best path to commercialize a medical 
device.  
After the components had been created, the team decided that the best way to conclude 
the recommendation for the best path of commercialization for Professor Pins’ cardiac patch 
would be to add a number ranking system to the matrix in order to learn just how well each 
business model matched the desires of Professor Pins as well as the current development stage of 
the cardiac patch. When considering the ranking system, the team immediately ruled out a one 
through two or one through three systems as many of the components were not “yes” “no” or 
“maybe” questions. The team chose the numbers one through five because it allowed for 
extreme, neutral and partial matches to all be addressed making it easy to follow and also 
allowed for the numbers to be easily changed as development of the cardiac patch continues.  
3.3 Cost-Benefit Analysis  
3.3.1 Costs 
Cardiac Patch Material Costs 
The main ingredients for the cardiac patch included fibrinogen, thrombin, and vellum 
paper. A patch can have any number of threads incorporated into it, depending upon what size is 
desired. For the purpose of the MQP, the project team analyzed costs based on one cardiac patch 
consisting of a single frame made up of twenty threads. Thrombin is purchased from Sigma, 
Fibrinogen is purchased from MP Biomedical, and the vellum paper can be found at any local 
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consumer goods company. Individual thread formation and organization in the frame takes about 
two hours of work, excluding the time required for threads to dry overnight.  
Currently, the development team produces patches on an individual basis. Taking the 
route of beginning a start-up or setting a goal of being acquired for commercialization purposes 
would cause a significant increase in costs to manufacture. According to McKinsey & Company, 
a consulting firm serving the medical device and pharmaceutical industries, the medical device 
industry spends, on average, about 76% of revenues on operations and manufacturing costs 
(Fuhr, 2013). These costs include cost of goods sold (41%), raw materials (17%), selling, 
general, and administration expenses (28%) and others (Fuhr, 2013). Additional manufacturing 
costs would also include a larger plant facility, proper sanitation supplies, adequate storage 
spaces, and quality processes. Cost savings could be met by buying patch materials in bulk 
through WPI's lab research suppliers. Otherwise, manufacturing the cardiac patch introduces a 
heavy cost burden for the development team.  
Cardiac Patch Indirect Costs 
Indirect costs for the development and commercialization of the cardiac patch and 
associated technology included FDA clinical approval, as well as the cost of securing intellectual 
property rights and patents.  
For a Class III medical device, as classified by the FDA, a total estimated time of six to 
twelve years is estimated to complete clinical FDA approval. The total timeline can be divided 
up into five development stages including concept, technology, prototype, pre-clinical, and 
clinical development. Each development stage requires a different level of funding, starting with 
government grants from sources such as the National Institutes of Health (NIH), to late-stage 
angel investing. A total of between $7 and $10.5 million is required for the complete process of 
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running clinicals and gaining FDA approval. At the end of this process, the medical technology 
can be ready to be licensed out, acquired by a larger company, or developed enough to start an 
independent venture. This entire process is outlined in Figure 6 (Stathopulos, 2013). 
 
Figure 6: Timeline and Budget for FDA Approval of a Class III Medical Device, 
Stathopulos, 2013 
In order to successfully commercialize the cardiac patch, the associated technology must 
be secured by strong intellectual property. Patents for medical technology, including filing and 
administrative fees, typically cost between $10,000 and $35,000 (Davidov, 2013). Inventors 
from universities disclose their idea to the Office of Technology Transfer or Management on-
campus. Licensing officers and intellectual property lawyers then evaluate the idea to ensure that 
the invention is novel, non-obvious, and can benefit society in some way. If the invention meets 
these criteria, the inventors and officers often file for a patent. As of 2016, universities reported 
an increase of 8.7% of invention disclosures and, similarly, patent applications filed were also up 
5% (Hawkins, 2016). 
Combining the cost of FDA approval and securing intellectual property for the cardiac 
patch results in a total estimated indirect cost of between $7.01 and $10.54 million, based on the 
assumption that both processes take a combined six to twelve years for completion. Table 2 
shows three scenarios for determining the total indirect cost of commercializing the cardiac patch 
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technology, based on time for FDA approval and securing intellectual property, as well as below 
average, average, and above average cases for the costs of each. The ranges provided above for 
time and costs were used as the below and above average figures, while the average column was 
calculated by averaging the ends of the ranges for each of the criteria.   
 Below Average Average Above Average 
Time (years) 6 9 12 
Indirect Cost per Patch    
FDA Regulatory Process $7.0 M $8.8 M $10.5 M 
IP Protection $10,000 $22,500 $35,000 
Total Indirect Cost $7.01 M $8.82 M $10.54 M 
Table 2: Cases for Determining Total Indirect Cost of Commercializing a Cardiac Patch 
Additionally, the project team calculated the indirect costs of commercialization on a per 
patch basis. The team estimated that with a below average case, the cardiac patch would reach 
10% of the potential 688,000 patients who survive following a heart attack and now seek medical 
treatment (86% of those who survive the nearly 800,000 heart attacks annually). This resulted in 
the below average demand number of patches per year, rounded up, to be 70,000. The same 
calculations were performed for an average case of meeting 20% of potential patients, or 140,000 
patches per year, as well as for an above average case of meeting 30% of potential patients, or 
210,000 patches per year. These per year demands were then multiplied by the respective time 
frames to estimate a total production of patches over six, nine, and twelve years. Finally, the 
project team divided the total indirect cost for each time period (Table 2) by the total production 
of patches to estimate the indirect cost per patch. These calculations are summarized in Table 3.     
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Time Period (years) 6 9  12 
% of Patients 10% 20% 30% 
Demand # of Patches (per year) 70,000 140,000 210,000 
Total Patches Over Time Period 420,000 1,260,000 2,520,000 
Total Costs, IP and FDA Approval $7.01 million $8.82 million $10.54 million 
Indirect Cost per Patch $16.70 $7.00 $4.20 
Table 3: Cases for Determining Indirect Cost per Patch 
The project team estimated the indirect cost per patch, including costs for intellectual property 
and FDA approval, to be $16.70 after six years, $7.00 after nine years, and $4.20 after twelve 
years. Figure 7 shows the indirect cost per patch decreasing over time.  
 
Figure 7: Indirect Cost per Patch Over Time  
 These calculations were based on several assumptions. The first assumption was that the 
developers would meet the potential patient population of 10%, 20% and 30%. Depending upon 
market conditions and acceptance of the cardiac patch technology, these percentages could be 
higher or lower. The second assumption was that production per year would be met, as well as 
stay consistent, throughout the estimated time period. Production numbers could realistically be 
altered due to increased competition too. It is also possible that if FDA approval and securing 
intellectual property rights takes longer than expected, costs per patch could increase from a 
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delay with initiating production. All in all, the project team was confident that production of the 
cardiac patch would increase over time to meet a higher demand, therefore spreading out the 
total indirect costs over a longer time period and reducing indirect costs per patch.  
3.3.2 Benefits 
Measuring the Value of a Cardiac Patch 
The project team found, through the use of several Harvard Business School cases, 
including, “Tengion: Bringing Regenerative Medicine to Life,” (Ofek, 2014), that there were two 
best practices for calculating the value of emerging medical technology, including: 
1. Savings from reduced future complications 
2. Increase in patients' quality of life 
In the case of the cardiac patch, these calculations would analyze the savings from reduced 
complications following a heart attack and the potential increase in quality of life following the 
implantation of a patch into a heart attack victim.  
First, the project team acknowledged the potential savings that a cardiac patch might 
bring patients, by reducing the chance of many common post-heart attack complications. Many 
of the complications following a heart attack still negatively impact the heart and its daily 
functioning. Some of these complications, treatments, and average costs can be found in Table 4. 
Complication Treatment Avg. Cost, U.S. 
Arrhythmia Implantable Cardioverter 
Defibrillator (ICD) 
$40,000 
Heart Valve Disease  Valve Replacement Surgery $40,000 
Coronary Artery Disease and 
Heart Failure 
Angioplasty 
Coronary Artery Bypass 
Surgery 
Heart Transplant Surgery 
$25,000 
$75,000 
$500,000 
 
Table 4: Common Complications Following a Heart Attack 
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Following a heart attack, those afflicted can experience an irregular heartbeat, or 
arrhythmia, as a result of the attack. An arrhythmia occurs when the heart’s natural pacemaker is 
out of rhythm, the heart’s conduction pathway is interrupted, in this situation by a heart attack, or 
the pacemaker is overcome by another part of the heart. The irregular beat can often be repaired 
by a temporary pacemaker or an implantable cardioverter defibrillator (ICD), which costs an 
average of $40,000 (Esposito, 2014). Heart valve disease presents another common complication 
for those experiencing a heart attack, which requires heart valves to be repaired or replaced if 
severely damaged. A heart valve replacement surgery can cost about $40,000 on average in the 
U.S. (Robinson, 2011). Most commonly, those who suffer through a heart attack and are left with 
damaged heart tissue face heart failure and coronary artery disease. Treatments range from 
angioplasty, inserting stents to open blocked arteries and vessels, to invasive coronary artery 
bypass surgery, each costing an average of $25,000 and $75,000 respectively (Delong, 2017). If 
heart failure persists, many patients will need a heart transplant surgery which costs upwards of 
$500,000 (Cox, 2017). Chronic conditions following a heart attack can include high blood 
pressure, high cholesterol, diabetes, depression, and others.  
In order to calculate total savings, the following equation should be calculated for each 
complication: 
Incidence x Avg. cost per incident 
If complications rise on an annual basis, the equation would be altered to include frequency per 
year and life expectancy, as follows: 
Incidence x Frequency x Avg. cost x Years until avg. maximum life expectancy   
Once these calculations have been made for each complication, a sum is taken to show the total 
potential cost savings. This indicates the potential savings from reducing post-heart attack 
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complications and associated costs, that can result from the successful implementation of a 
cardiac patch.  
Second, the project team measured the value of the cardiac patch through its potential 
increase in quality of life for patients. The quality of life measurement takes the value of a 
healthy year of human life and multiplies this by the percentage improvement that a cardiac 
patch can provide patients. The result provides an estimate of the increase in quality of life to 
patients who receive a cardiac patch. However, two important limitations were noted by the 
project team. First, further development is required before a percentage improvement can be 
calculated for the cardiac patch. Second, the value of a healthy year of human life can be debated 
when performing these types of calculations. As a result, the quality of life increase value of the 
cardiac patch may differ throughout development and should be used only as an estimated range 
of increase in value to patients.  
Therefore, the cardiac patch development team should use both the reduced post-heart 
attack complication savings and increase in quality of life calculations in order to further show 
the value of the cardiac patch throughout the commercialization process.  
Potential Income Stream from Licensing 
Licensing offers a unique method of generating income from the intellectual property of 
medical device technology. Upfront license fees for the medical device industry range from 
between $25,000 and $50,000, depending upon the technology and market conditions. These 
upfront fees are collected at the beginning of the contract, after negotiations between licensees 
and licensors have been finalized. Royalties for the medical device industry are typically in the 
range of 0.5% to 7% (Shimasaki, 2009). A summary of these projected royalties can be seen in 
Table 5. 
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Table 5: Comparison of Licensing Fees and Royalties 
Payments are set out in a predetermined schedule during negotiations. Royalties can be 
set on a per product basis as it is sold, or calculated by the percent increase in operating margin 
that a licensee experiences due to the licensed intellectual property. Well established companies 
who act as licensees may be more willing to make cash royalties to licensors, since they have the 
necessary capital. On the other hand, smaller start-ups may offer licensors stock in the company, 
since cash flow is so restricted in this entity (Dr. Rawat, Personal Communication, January 30, 
2018). Therefore, licensing provides an easy method for an inventor to make money from their 
intellectual property, without many of the risks associated with commercialization.   
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Chapter 4: Recommendations 
The project team recommends that the best commercial pathway for the emerging cardiac 
patch technology is licensing. The team recommends that the WPI cardiac patch development 
team pursue a licensing agreement that, specifically: 
1. Targets medical device companies, with or without an established cardiac patch 
division, as the licensee(s)   
2. Has non-exclusive terms 
3. Licenses the cardiac patch technology globally 
4. Is industry-specific  
5. Fits the technology into existing medical codes for insurance purposes 
While the project team found that licensing will provide for the best commercialization strategy 
at the current stage of development, it is also important to note that this recommendation may 
change as the cardiac patch development process continues over time. This report analyzed two 
additional medical technology go-to-market strategies for use by the development team, if the 
commercialization process were to take a different route in the future. 
4.1 Targets Medical Device Companies as Licensees 
The project team recommends that Professor Pins and the development team seek 
licensing agreements with medical device companies as the licensees. The medical device 
companies can be either, 
1. Those with an established cardiac patch division, looking for new technology, or 
2. Those without an established cardiac patch division, looking to break into this industry 
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Medical device companies with well-established cardiac divisions may be looking for new 
technology in order to further drive innovation. Depending upon company needs, they may feel 
that the cardiac patch technology could fit into a different level of innovation, as seen in Figure 8.  
 
Figure 8: Model of Product Innovation for Medical Devices, Stathopulos, 2013 
The star here represents Professor Pins’ cardiac patch as a technological innovation: a new 
technology that can be applied to an existing medical use. Advantages of these companies being a 
licensee is that well-established capital budgets for cash royalty payments, as well as experience 
in the industry, so as to not misuse the technology. Medical device companies without an 
established cardiac division may be looking to expand into the industry, without the need for in-
house research and development costs. However, these licensees may misuse the technology or 
misunderstand the market without experience in the industry. Both options allow for royalty 
payments and a way to get the cardiac patch technology to the market quickly, which is why the 
project team recommends them as the best licensee options.  
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 A third option for a licensee is that of medical device start-ups, looking to break into a new 
and unexplored market. The advantage of this licensee over the others is that of attractive options 
for Professor Pins to stay more involved with the technology, marketing, and manufacturing 
efforts. However, due to restricted cash flow, start-ups are more likely to offer equity within the 
company over cash royalty payments, which is why these licensees would be the least 
recommended by the project team. 
Because a licensing deal relies solely on the other companies’ interest in the use of the 
inventor's technology, it is vital to establish potential customers early in product development. This 
leads the team to the next vital aspect of managing a licensing deal: being flexible. The owner of 
the intellectual property, thus likely the inventor of a product, is going to be extremely passionate 
about their product and the course that they think it should take. A licensing agreement or "field 
of license" allows those parameters to be identified early on in the agreement. 
4.2 Has Non-Exclusive Terms 
The project team recommends that the licensing deal have non-exclusive terms. 
Exclusivity refers to who is allowed to use the intellectual property rights, in terms of a licensing 
agreement (Shkopiak, 2018). Exclusivity gives all the rights to a single licensee, or in this case, a 
single medical device company. Non-exclusive rights allow the licensor to license the 
intellectual property to more than one single licensee, or multiple companies, start-ups, or other 
licensees. During negotiations, companies may offer higher royalties for exclusivity to their 
company for rights, so that competitors are not able to license the same intellectual property to 
compete. Licensors seek non-exclusivity, so that multiple licensees may exploit the intellectual 
property. The project team found that non-exclusivity was ideal for the licensing agreement 
because it is riskier for a licensor to have an exclusive deal. The licensee has the ability to shelf 
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the technology or drop out of the agreement, potentially leaving the licensor with nothing. 
However, non-exclusive deals are much less likely to be negotiated.  
4.3 Licenses the Cardiac Patch Technology Globally 
Licensing is one way to penetrate a foreign market, especially if that market is already 
closed off to imports. However, before a product is to enter a foreign market with a licensing 
agreement, it is crucial that exclusive property rights are obtained through a patent, copyright, or 
trademark (Gardner, 2013). Once those are obtained, there are six key components and 
provisions to be included in a foreign licensing agreement: 
1. Foreign approval of licensed goods 
2. Payment plans, currency conversion, as well as international tariff determination 
3. Consent to jurisdiction 
4. Choice of law 
5. Dealing with conflicts through arbitration 
6. Foreign patent 
 The project team recommends that the licensing agreement enters markets 
internationally, including within the United States, Europe, Japan, and China, based on their 
technology platforms and status in the medical device field. These nations all have strong 
medical device markets which means competition is high as there are products with patents 
already secured. 
 Asia Pacific dominated the overall market in terms of revenue share as they take up about 
59% of the total revenue in the cardiovascular and soft tissue repair patch market (Grandview 
Research, 2016). This is due the large population base of this region, as well as their 
susceptibility to cardiovascular diseases that typically require surgery. Also, due to the constantly 
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improving healthcare structure, this region has a higher penetration of cardiac patches which can 
boost market growth. This region includes China, Japan, and Australia as main competitors in 
the cardiovascular and soft tissue repair market. 
Cardiovascular disease is one of the leading causes of death in Asia and 57% of 16.5 
million people who die from this disease annually are from Asia. This number is destined to 
continually increase as residents of Asia have changed their lifestyle, and are eating Western fast 
food, they are smoking more, and exercising less. Because of this, there is more of a focus on the 
diagnosis, treatment, and prevention of cardiovascular diseases, and a rising demand for medical 
devices in Asia. The current market in Asia is worth 11.5 billion USD with a 11% annual 
growth. In 2017, Asia took up 29% of the market, which is expected to grow to 38% in 9 years 
(MassDevice, 2012). 
         China’s market for coronary artery disease patients is 19.8 million out of the total 
population of 1.38 billion people. With China’s rapidly aging population, there is a greater need 
for medical devices to aid in the solution to the problem of coronary artery disease. Although a 
major portion of the medical device companies in China are foreign firms from the United States 
or Europe, local Chinese companies such as Lepu and MicroPort manufacture Class III Medical 
Devices (MassDevice, 2012). 
         Japan’s market consists of a rapidly aging population with a rising number of people with 
diabetes as well as young smokers. This has greatly increased the number of people who suffer 
from cardiovascular disease in Japan, allowing for a growth in the cardiovascular device market. 
Japan has high government healthcare standards, which opens up the market for new 
interventional healthcare solutions. 
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Europe and the United States share the majority of the cardiac patch market. International 
companies tend to have their firms located in Europe because of their understanding of the 
market and the need for new approaches to medicine. 
4.4 Is Industry-Specific 
The project team recommends that the licensing agreement for commercialization of the 
cardiac patch technology be industry-specific. This would allow the development team to utilize 
the technology as a platform, for future applications. A licensing agreement for the cardiac patch 
technology, with non-exclusive and global terms, allows the patch to get to the market faster, in 
order to treat patients suffering from myocardial infarctions as soon as possible. However, due 
diligence with securing strong intellectual property rights will allow Professor Pins and the 
development team to continue researching to determine if the technology can be applied to other 
parts of the body, and, therefore, other industries, as well. This sets up the possibility for 
additional licensing agreements in the future, outside of the cardiac industry.  
The team also strongly recommends that the development team use a Freedom to Operate 
opinion before filing for the patent. Before pursuing commercialization, it is crucial that prior 
art, or any evidence that one’s device or invention is already known, is overcome in order to 
introduce a product.  
4.5 Fits the Technology into Existing Medical Codes 
Medical device coding is any extremely complex process vital to the success of any 
medical device. The project team recommends that the cardiac patch technology fits into existing 
medical code(s), as this will greatly speed up the process of FDA approval and insurance 
coverage for patients.  
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According to the Atticus Group, a business development firm for medical devices, coding 
acts as “the language of insurers” (The Atticus Group, 2017). Every aspect of a medical device, 
from the supplies all the way to the implantation procedures, is broken down in the seemingly 
foreign language of medical device codes. These codes are listed on insurance claims prepared 
by hospitals and doctors to ensure the proper payment by insurance companies for the service 
and use of the medical device. Proper coding for a medical device is vital to a streamlined and 
organized payment process. 
The first step in establishing a coding sequence for any medical device is to apply to the 
American Medical Association (AMA) for Current Procedural Terminology (CPT) codes. CPT 
codes classify medical, surgical and diagnostic procedures into a simplified number system 
simplifying the vast number of procedures used in today’s healthcare system (Rouse, 2015). 
There are three categories in CPT codes broken down to numbers one through three, with more 
detail on each provided in Chapter 5.  
4.6 Recommended Next Steps 
Based on the team's recommendations, the next steps in order to evaluate the commercial 
pathway of the emerging cardiac patch technology should be to: 
1. Secure intellectual property and patent position 
2. Gain FDA (or equivalent) approval 
3. Measure cardiologist/cardiac surgeon interest in the cardiac patch 
4. Determine the medical code that best fits the properties of the patch, for easier adoption 
of the product by insurance companies 
5. Explore additional niche markets with the technology platform 
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Additionally, the project team recommends that the cardiac patch development team take 
advantage of their close relationship with a university Technology Transfer Office. These offices 
at WPI and UMASS Medical are able to provide support to the development team throughout the 
product’s clinical trials, FDA approval, and licensing royalty negotiations. The project team also 
recommends collaborating with a medical device consultant in order to gain access to seemingly 
confidential industry information. 
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Chapter 5: Discussion 
5.1 Myocardial Infarction Causes 
Most heart attacks occur after a blood clot forms and, with plaque build-up over time, 
blocks blood flow to and from the coronary artery (“Understanding Heart Attack,” 2017). These 
blockages are most commonly the result of coronary artery disease, or “atherosclerosis.” 
Coronary artery disease is triggered by high cholesterol, high blood pressure, obesity, stress, and 
smoking (“Understanding Heart Attack,” 2017). Diabetes and heart disease can also increase an 
individual’s chances of suffering from a heart attack. 
5.2 Other Current Medical Treatments and Solutions 
Other medical treatments and solutions for myocardial infarctions include: 
5.2.1 Balloon Stents 
The insertion of a balloon stent has been a commonplace solution around the world to 
treat the effects of and prevent myocardial infarctions for over ten years with over two million 
people each year opting for this type of treatment (Medtronic, 2017). The procedure, called an 
angioplasty, is minimally invasive and extremely effective.  
An initial angioplasty determines the exact location of any and all blockages in the 
coronary artery system that need to receive treatment. A catheter is inserted into the arterial 
system via a small insertion in either the leg or arm to the location(s) of the blockages using x-
ray guidance (Medtronic, 2017). Once the wire is in place, a balloon is delivered to the blockage. 
The balloon is inflated and deflated multiple times to clear the site of plaque build up to allow 
blood flow to restore. Once complete, an additional balloon is sent via the catheter to the 
blockage site, but this time mounted with a stent. As the second balloon is inflated, the stent is 
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forced open and locked into place to hold the artery open as a permanent solution to keep the 
blockage site clear. This procedure instantly relieves clogged arteries proving extremely effective 
to treat current and potential issues of arterial plaque buildup that could in turn lead to a 
myocardial infarction (American Heart Association, 2015).  
Advancements on this technology front have arisen from companies incorporating 
medication and drug delivery into this treatment. The introduction of drug delivering stents has 
come to market as well as the method of not using a stent at all and just using a drug-delivering 
balloon. Instead of attaching a stent to keep the artery open, Medtronic has begun coating the 
second balloon in the operation with an anti-proliferative medication. This has become another 
popular use of the balloon technology posing possibly more effective results than a traditional 
balloon-stent procedure. 
The use of balloon stents and additional procedures is commonplace amongst hospitals 
across the world. A minimally invasive procedure that can virtually stop a heart attack, the 
benefits of this procedure are great for an emergency procedure.  
Balloon stents have proven to be quite a short-term solution with restenosis rates being 
recorded between 3% to 20% within six months though some studies have found rates as high as 
40% (Osterweil, 2017). Additionally, balloon stent procedures do not treat any issue that may 
have been damaged due to the previously blocked artery. any damage that may have been done 
to the tissue of the myocardium is not addressed using this procedure. Ranging at costs of 
$15,000 to $50,000 as just a base cost, a balloon stent procedure is a high cost for a seemingly 
temporary solution (Medigo, 2018). 
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Figure 9: Balloon Stent Procedure, Livingston, 2015 
5.2.2 Medication 
Medications are commonplace in hospitals in order to provide physical relief to patients 
as well as reduce the effects associated with a patient who has suffered a myocardial infarction. 
According to the American Heart Association, there are eleven types of drugs used to treat the 
effects of a myocardial infarction. All of these drugs are aimed to solve varying issues that are 
the result of the occurrence of an infarct and have varying degrees of success (American Heart 
Association, 2017). 
 Angiotensin-Converting-Enzyme (ACE) Inhibitor 
o Stops the production of the enzyme that produced angiotensin II which works to 
constrain blood vessels and raise blood pressure (Mayo Clinic Staff, 2016) 
  Angiotensin II Receptor Blockers (or Inhibitors) 
o Prevents angiotensin II from performing its function of constricting blood vessels 
and raising blood pressure (Mayo Clinic Staff, 2016) 
  Angiotensin-Receptor Neprilysin Inhibitors (ARNIs) 
o Neprilysin inhibitor and benefits of ARB drugs (American Heart Association, 
2017) 
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  If Channel Blocker (or Inhibitor) 
o Slows heart rate (American Heart Association, 2017)  
  Beta Blockers 
o Slows heart rate (American Heart Association, 2017) 
  Aldosterone Antagonists 
o Blood thinner (American Heart Association, 2017) 
  Hydralazine and isosorbide dinitrate 
o Recommended for African American patients as a solution to reducing 
hypertension (Taylor, 2004) 
  Diuretics 
o Rid the body of excess fluids and sodium that can cause unnecessary strain on the 
heart to process (American Heart Association, 2017) 
 Anticoagulants  
o Blood thinner 
 Statins 
o Prevent the production of hydroxy-methylglutaryl-coenzyme A reductase, a 
cholesterol producing enzyme (Ogbru, 2018) 
 Digoxin 
o Controls rhythm of heart beat through increasing production of ATPase, an 
enzyme that promotes contractile movements within the heart (Ogbru, 2018) 
Though unique combinations of these individual drugs are often used to treat each patient, it is 
clear that there is not one definitive drug solution that can be taken in the long run. 
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5.2.3 Direct injection 
Direct injection is another solution to the problem of myocardial infarctions. Direct 
injection can be done numerous ways: intracardiac injection, surgical injection, as well as robotic 
injection. 
Intracardiac injection can be done directly through the skin in order to provide 
therapeutic cells to the heart. This is done by directly inserting a needle into the myocardium of 
the heart chamber. This form of injection method is minimally invasive as well as inexpensive as 
it uses common procedures and syringes. There can be a few drawbacks with this method as 
there can be risks to the patient that is receiving this injection. Lacerations of the myocardium as 
well as a collapsed lung can occur if the procedure is not done properly. The stomach wall may 
also be punctured. Although this procedure is minimally invasive, the insertion of this needle can 
be quite painful for the patient (Lamberg, 2013). 
The next type of injection occurs during heart surgery. It is an additional procedure that 
can be done to improve heart function after surgery. Although this surgery provides direct 
contact with the heart as the surgeon has access to it, it is much more invasive. A syringe is used 
to directly inject the autologous cells into the heart. This method is not fully supported by 
surgeons as it is in addition to open surgery, and because it does not have a high success rate 
(approximately 11%), surgeons are not as willing to perform it (US National Library of 
Medicine, 2012). 
Finally, there is new technology out there in order to perform a robotic injection paired 
with a hydrogel injection. The HeartLander, a crawling robot used for this injection, is minimally 
invasive and has the ability to perform these injections accurately. Through the control of a 
surgeon, this robot can enter the chest through an incision within the sternum, adhere to the 
heart, travel to the correct location of the infarct, and administer cell therapy. Although this 
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testing has only been done on pig hearts, it has seen success. This robot can move to any location 
on the pericardial surface after a 10 mm incision has been made. This robot can reach the target 
location of the treatment through sensor data that determines where the infarct is, as the surgeon 
is the one who guides it remotely. Once the robot reaches the desired location, it is in a stable 
state in order to provide the therapeutic treatment with a needle. For myocardial infarctions, a 
dye is injected into the site from outside of the animal, and then cells can be delivered to the 
correct depth of the myocardium. The benefits of this method include its stability, localized 
sensing, no potential for lung deflation, as well as access to the heart. However, this method 
seems as if it will be an expensive one as sensors are required as well as the purchase of the robot 
itself for each procedure. The other procedures are done using medical tools that are already on 
hand, making this the more expensive choice (Robotics Institute, n.d.). 
5.2.4 IV Drip 
The next type of injection is done intravenously through an IV drip directly into the radial 
vein. When focusing on the heart, there is a high concentration of cells that are being delivered to 
the body through this drip and travel directly to the affected area of the heart. As this is the most 
minimally invasive of its competition, there can be complications due to the path of delivery. As 
these cells are delivered directly into the bloodstream, they can pass through other organs of the 
body such as the lungs and can form clumps of cells within the body. Doctors who inject these 
cells have no way to control where these cells attach in the body, giving it a very small chance 
that these cells attach to the heart wall rather than other organs (Martins de Oliveira, n.d.). 
5.2.5 Cardiac Patches 
The function of a cardiac patch is to replace the dead or damaged tissue that develops as a 
result of a myocardial infarction.  Most commonly used in the operating room today are 
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synthetic, a-cellular patches. Traditionally, patches are constructed of either polyethylene 
terephthalate (PET) or (expanded polytetrafluoroethylene) ePTFE. 
The thermoplastic polymer PET is best recognized by the brand name Dacron. Dacron is 
a highly favored biomaterial to use as the scaffolding material of a cardiac patch due to its 
promotion of endothelialization while maintaining virtually no calcification or tissue overgrowth 
in the process (An Introduction to PET, n.d.).   In comparison to PET grafts, ePTFE grafts are 
used much less, but are the basis to a wide number of grafts created by one of the top material 
science companies in the world, Gore. ePTFE poses the benefit of lower thrombogenicity, or the 
tendency of a material that comes in contact with blood to cause a clot, as well as not being 
physiologically harmful to the site in which it is placed. However, it can be mechanically weak, 
which is a disadvantage when it comes to heart function when trying to imitate the mechanical 
and electrical properties of the heart (The Properties and Advantages of ePTFE, 2016). 
5.3 Stakeholders 
5.3.1 Biomedical Engineer 
Biomedical engineers are important stakeholders in the cardiac patch industry as they are 
the ones who will continue to build the technology. They constantly invent and discover new 
solutions to problems within the healthcare field, such as the creation of the cardiac patch to 
solve the prevalent cardiac disease issue that is plaguing the world. Biomedical engineers have 
an important role in development, as the patch has the potential to be used for more than just 
cardiac infarcts. Within the cardiac patch market there is a high growth potential, which is 
beneficial to biomedical engineers as they will constantly have a need for their new and 
innovative research. 
51 
 
5.3.2 Medical Device Companies 
         Medical device companies are important stakeholders in the cardiac patch industry as 
they are the ones who sell the products that the biomedical engineers invent and create. With a 
strong patent and the approval of this cardiac patch, these companies would be able to add this 
cardiac patch to their repertoire through a licensing arrangement, giving them an advantage in 
the market that they are constantly trying to be the main competitor in. These companies play an 
important role as they would be responsible for manufacturing the patch as well as getting it to 
the market. With that, this patch would be able to generate revenue for the medical device 
companies as well as strengthen their brand. 
5.3.3 Hospitals 
Since cardiac diseases are the leading cause of death, hospitals are increasingly looking 
for improved technology in order to better treat those suffering from myocardial infarctions. 
Often times, when a patient suffers a heart attack, they are admitted to the coronary care unit, or 
CCU. There they are monitored closely by a cardiac care team. Hospitals and staff will share in 
the responsibility for risk related to the cardiac patch technology. It is up to the hospital to ensure 
safety and efficacy of the patch, as well as to determine which patients would be best suited for 
implantation. The hospital is also responsible for employing cardiologists who implant the 
cardiac patch and monitor the patient over time, as well as training the staff on the proper use of 
the new technology. While the cardiac patch may provide benefits to the hospital with decreased 
rate of mortality from heart attacks, the hospital would also be responsible for taking on the risks 
and complications of bridging the gap between the technology manufacturers and patients. 
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5.3.4 Cardiac Surgeons 
Cardiac surgeons would be taking on extremely high risk when adopting this new 
technology into their practice. At stake is the lives of their patients, their career and reputation in 
the medical field. The surgeons are responsible for not only the successful implantation of the 
cardiac patch but ensuring the long-term success of the device for the patient. 
5.3.5 Patients 
The patient who receives a cardiac patch is the stakeholder that would be most affected 
by the commercialization of this new technology. Ensuring that the cardiac patch delivers on the 
functions it promises to deliver is vital to patients. 
It is imperative to the success of this cardiac patch that the consumer has a clear 
understanding of the benefit this product poses to them over the competition. This includes the 
technology benefits of the device over the competition, recovery process and long-term behavior 
of the device. It is the team’s opinion that Dr. Pins should market this device as having the 
advantage of having tunable mechanical and biologic functions. Dr. Pins has identified a 
significant gap in the market for a device that also integrates with the tissue restoring mechanical 
functions and contractility. While the cardiac patches on the market today provide structural 
support for the heart after the removal of damaged myocardial tissue, Pins’ patch does this as 
well as incorporate tunable functions. 
5.4 Risk Assessment 
When commercializing medical device technology, there are various levels of 
development risk depending upon if the technology is “new” or “existing,” as well if the clinical 
use of the technology is “new” or “existing.” The uncertainty of risk increases as both the 
technology and clinical use are newer to the market (Stathopulos, 2013). Likewise, low 
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uncertainty matches a technology already in the market with an existing medical use. The project 
team found that the emerging cardiac patch technology from Professor Pins and the development 
team at WPI fits into a “new” medical technology category, with an “existing” clinical use. The 
technology specific to this patch is new and improved, while the clinical use is existing, since 
cardiac patches in general already exist. Figure 10 shows the level of development risk scale, as 
well as where the cardiac patch fits indicated by the star.  
 
Figure 10: Levels of Development Risk, Stathopulos, 2013 
  
In addition to development risk levels, there are also a number of legal, financial, and 
regulatory risks associated with commercializing the cardiac patch technology. Legal risks 
include gaining proper patents for the technology to protect against infringement, as well as 
adhering to contracts with any partners involved in the process. Financial risks include restricted 
cash flow, and the reliance on capital raised from investors and venture capitalists. Regulatory 
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risks refer to the timeline for FDA approval, since a Class III medical device requires extensive 
clinical studies, extending the time needed for the total approval process. Changes in compliance 
laws throughout different regions may also add regulatory risk, as the changes would need to be 
tracked when licensing globally.  
5.5 Intellectual Property 
5.5.1 United States of America 
In the United States of America, the rights to intellectual property are permitted in the 
form of a patent. The United States Patent and Trademark Office (USPTO) is the government 
organization responsible for reviewing the grants and applications submitted by prospective 
inventors and the distribution of the patents (USPTO, 2015). 
Securing a patent for an invention is a common procedure for anyone looking to 
capitalize on their invention. Securing a patent for a technology builds a large amount value for 
the owner by developing intangible assets, developing legitimacy in the industry, total control of 
the technology (Thayer, 2013). 
There are three types of patents distributed by the USPTO. The names and definitions 
given by the USPO are as follows: 
“Utility patents may be granted to anyone who invents or discovers any new and useful process, 
machine, article of manufacture, or composition of matter, or any new and useful improvement 
thereof. Design patents may be granted to anyone who invents a new, original, and ornamental 
design for an article of manufacture. Plant patents may be granted to anyone who invents or 
discovers and asexually reproduces any distinct and new variety of plant” (USPTO, 2015). 
After the patent is distributed, it is the responsibility of the patent owner to protect their 
property from others using it, not the USPTO. A common fallacy is that a patent grants the 
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owner the right to make, use and sell the invention in the United States. On the contrary, a patent 
gives the inventor of the product the rights to seek legal action toward anyone infringing on 
one’s patent (USPTO, 2015) (Frisina, 2015). A patented process or technology can contain other 
processes or technologies that are protected by another party preventing the free use of one’s 
invention. For examples, a patent for invention "C" could use an implantation process protected 
by patent "A" as a core component of the production of the product. Without a legal license to 
use patent "A", patent "C" cannot be created, used or sold without infringing upon patent "A". 
In 2016 alone, there were a total of 4,520 patent infringement cases in the United States 
of America; all which came with a high price tag attached to each (Brachmann, 2017). 
According to the 2017 Report of the Economic Survey published by the American Intellectual 
Property Association, the average legal bill for any party involved in a case, where less than $1 
million is at risk, is $800,000 (Nayak, 2017). Where the stakes are higher with $1 to $10 million 
dollars at risk, the infringement case costs, on average, $1.7 million dollars (Nayak, 2017). 
In order to avoid situations like this, early investigation in the form of a Freedom to 
Operate Opinion has become highly favored by industry experts, even going as far as to be seen 
just as important as having a patent. 
5.5.2 Freedom to Operate Opinion 
A Freedom to Operate Opinion (FTO) is a service that aims to avoid patent infringement 
lawsuits or the standstill of a patent. This is accomplished with an FTO by investigating 
outstanding or pending patents that may affect one's ability to use the filing patent. The sole 
purpose of an FTO is to ensure that one is able to freely practice the protected technology in the 
industry, which is one of the most vital components for commercializing any product. 
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A FTO gives a potential investor, partner and of course the inventor a professional 
document that can ensure to a certain degree, the allowance of the use of the patent in the 
industry. From the inventor’s point of view, the attractiveness of an FTO is that, if filed early 
enough, it offers the filer the ability to alter their product or service before filing as to ensure the 
allowance to use after they have been granted the patent. 
In the medical device industry specifically, an FTO is an extremely attractive investment 
to make considering the amount of time and money that goes into the development of a medical 
device. An FTO is best to be conducted as soon as possible in the development of a medical 
device so as to ensure that all aspects of the device are allowed to be freely exercised down to the 
way the device may be implanted. Seeking out an FTO as soon as possible will allow for 
efficiency and time for the proper adjustments to be made to any patents the exercising of the use 
of the device may be currently infringing upon. However, in an industry such as cardiac medical 
devices where the market is growing, getting a proper FTO is extremely difficult. 
5.5.3 International 
A U.S. patent protects this intellectual property of an invention only within the United 
States of America and its territories. Patent laws differ from country to country and must be 
individually investigated and filed in order to obtain intellectual property protection outside of 
the United States (USPTO, 2009). 
5.6 Medical Device Coding and Insurance 
When a medical device is ready for distribution, after receiving clearance from the FDA, 
a plan for reimbursement must be well established in order to simplify the exchange of the 
product for capital. Though hospitals and doctors are the entities that use medical devices, more 
often than not, they do not directly pay for them. Instead, insurance companies are usually 
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responsible to cover their customers’ expenses. Insurance agencies can be simply divided into 
two primary categories of private entities (Blue Cross Blue Shield, Harvard Pilgrim, etc.) or 
government entities (Medicare, Medicaid, etc.). No matter the third party though, any third party 
requires baseline components within the three categories of coverage, coding and payment 
(Mensh, 2006). 
Category 1 codes contain the latest and greatest in medical device procedures (Rouse, 
2015). These procedures are FDA approved and seen as commonplace in hospitals and doctors’ 
offices worldwide (Rouse, 2015). Furthermore, CPT codes are divided into six primary 
categories labeled evaluation and management, pathology and laboratory anesthesiology, 
radiology, surgery and medicine.  
Category 2 codes are used in conjunction with Category 1 codes to further define the 
characteristics of the procedure performed. This set of codes is not mandatory but is only used 
when Category 1 codes are present on the insurance claim. Category 3 CPT codes are temporary 
codes appointed to breakthrough and upcoming medical technologies that may just be breaking 
into industry. Procedures that hold Category 3 codes may not have FDA approval or even any 
clinical results but are a part of ongoing human studies (Rouse, 2015). CPT codes are used in 
conjunction with an additional set of codes called ICD-10 codes. 
ICD-10 or International Classification of Disease, replaced the ICD-9 codes in 2015, 
ICD-10 was made mandatory for use of anyone covered by the Health Insurance Portability 
Accountability Act, including all hospitals, physicians and insurance companies (AthenaHealth, 
2017). There are currently more than 68,000 codes in the ICD-10 alone showing the challenges 
presented in classifying a device. The ICD-10 codes are vital to the continuous improvement of 
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the healthcare system in their specificity of diseases that further allow the creation of data and 
patterns to be analyzed by industry experts about diseases. 
The Healthcare Common Procedural Coding System II (HCPS II) is the third and final set 
of codes needed to be addressed in the commercialization of a medical device. The HCPSII 
system is defined by the Centers for Medicare and Medicaid Services (CMS) as CMS, “a 
standardized coding system that is used primarily to identify products, supplies, and services not 
included in the CPT code set jurisdiction, such as ambulance services and durable medical 
equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's 
office.” (Centers for Medicare and Medicaid Services, 2015).  
5.7 Regulatory Standards 
 Regulatory standards vary from country to country, as this next section addresses the 
regulatory process for the United States, Japan, China, and countries within Europe. 
5.7.1 United States 
 Within the United States, in order for a medical device to be able to be put onto the 
market, it must pass the Food and Drug Association (FDA) regulatory process. The general FDA 
process can be seen below in Figure 11. 
 
Figure 11: Food and Drug Association Pathway 
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 The FDA requires that clinical trials done in the United States, with five hundred to one 
thousand patients in order for it to pass through and onto the market. Medical devices in the 
United States require Pre-Market Approval (PMA), or the scientific and regulatory process of the 
FDA that a Class III medical device needs to be reviewed for to evaluate the safety as well as 
usability of said device. A PMA in order to be passed by the FDA requires sufficient data and 
evidence that the medical device in question is safe and efficient for its intended use, which can 
be through the clinical trials mentioned above (Center for Devices and Radiological Health, 
n.d.). The entirety of this process can cost between $5 and $10 million, spanning over a period of 
five to ten years. The regulatory process in the United States, in detail, can be seen in Figure 12. 
 
Figure 12: United States Regulatory Pathway, Stathopulos, 2013 
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5.7.2 Japan 
 In Japan, as within the United States, a Class III medical device has to go through an 
agency for approval prior to entering the market. Medical devices in Japan need approval from 
the Pharmaceuticals and Medical Devices Agency (PMDA), which is a Japanese governmental 
organization that functions similarly to that of the FDA as it is in compliance with ISO 13485, 
which is the agreed upon international standard and requirements for quality as well as for the 
regulatory processes of medical devices (ISO-Medical Devices, 2018). However, the process for 
each device that goes through the PMDA varies based on the risk associated with the device, 
rather than based on the type of device. In regards to local clinical trials, the number of patients 
for each trial is based on the risk associated with the device as well. For a high risk device such 
as a cardiac patch, there are from four hundred to six hundred patients required. The costs for 
completing these clinical trials are high and can be lengthy in order to gain the certificate of 
approval. However, once approval is gained for that device, the certificate never expires, unlike 
in other nations.  
5.7.3 China 
 The process for getting approval in China has similarities and differences to that of other 
nations. The device must go through the Chinese Food and Drug Association (CFDA). However, 
when bringing a device that is created in an outside nation from China, there must be approval 
from the home country of said device through a certificate of free sale as well as a certificate to 
the foreign government. This can lengthen the process as it really is two separate approval 
processes. Once the device is approved in its home nation and has retained an ISO 13485 
certificate, there must be an agent located in China that will coordinate the CFDA device 
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registration. With a Class III device, there must be local clinical testing done in China as well as 
a product comparison to one of equivalence that already exists in China. The number of patients 
for clinical trials can vary as well as fees, but the time frame for approval can be the longest as 
there is authorization required from home nations and all documentation of the results and 
evaluations must be in the simplest form of Chinese before they can be submitted to the CFDA 
for approval. Once approved, the certificate does not expire for five years (Chinese Food and 
Drug Association, 2013). 
5.7.4 Europe 
 In certain nations of Europe, the equivalent of the FDA process within the United States 
is a process through the European Medicines Agency (EMA). However, with medical devices, 
they must receive a CE mark, or a mark that indicates a product conforms to health, safety, and 
environmental standards of a nation within Europe, before it can be distributed to other nations 
within the European Union. In order to meet CE guidelines, clinical trials must be completed 
locally within Europe with patient numbers that are equivalent to those of similar products that 
have already been approved. Once a CE certificate gets received, the firm can then register the 
device to be distributed within certain countries. This certificate is valid for up to a year and is up 
for auditing in all years after. The process of receiving a CE mark can cost from two to three 
million dollars. 
5.8 Team Growth and Examination 
Since all students in the team majored in Management Engineering with a concentration 
in Biomedical Engineering, each has received an education in both the business and biomedical 
engineering spectrums at WPI. Finding this balance, in addition to a diverse advisory team 
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background, the team had to ensure that the material they chose to highlight in team 
presentations as to satisfy not only themselves, but the professors on the project with a wide 
variety of professional backgrounds. Throughout the first seven weeks, the team had to 
overcome the challenge of developing a language and style of presentation that could hold the 
attention and understanding of both a businessman and biomedical engineer. Originally, the 
project team faced this challenge through week seven. Next, the respective functional 
requirements were to be established. Perfecting these processes took the rest of the term and was 
done in conjunction with exploring more about the technology which began in week six.  
By spending a lengthy amount of time focusing on the decomposition, the team learned 
the importance of having proper resources and not trying to “reinvent the wheel”. Maintaining 
confidence in presentations and having proper factual support was something that the project 
team learned was vital for acting as consultants to Professor Pins on the project. This allowed the 
project team to support their stance knowing that they put the work in to eliminate other options 
and determine that the decision was factually supported. Before taking action, it was important to 
evaluate and plan the work ahead, so the use of axiomatic design was key in creating a fully 
utilized and organized roadmap for future weeks. 
Additionally, the team discovered the importance of only choosing one specific, and 
narrow, problem to tackle. In the beginning of the project, the team was enthusiastic about 
developing an entire business plan and value proposition for Professor Pins’ cardiac patch. The 
team's research and writing included analyzing patents and intellectual property on the device, 
evaluating a number of different possible business routes, and analyzing competition and need 
for the product in the marketplace. After a few meetings with the project team's advisors, Mr. Joe 
Vignaly, and Dr. Yael Schwartz, the team quickly realized that trying to achieve all of these 
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different pieces would be an impossible task. The project team soon came to the conclusion that, 
despite each of these being an important problem in themselves, they could only focus in one of 
these areas for the project. This realization provided the project team with improved focus on 
what the MQP actually was, and how they were able to produce a valuable and useful project in 
the end. 
Finally, the team learned the importance of collaborating with industry experts who have 
the experience to catalyze their thinking process and understanding of the problem at hand. 
Going into this project, the team expected to tackle this issue amongst only themselves and 
project advisors. The primary takeaway from the first seven weeks of the project was that, 
although group discussion and brainstorming are important, ultimate success relies on insight 
from industry experts who have experience completing such projects. Speaking with those such 
as Joe Vignaly and Yael Schwartz helped the project team pick up common themes among 
commercialization, which gave the project team a true starting point for the project. 
While the project team was confident in the final go-to-market commercialization 
strategy recommended to the cardiac patch development team at the conclusion of the project, it 
should be noted that since the cardiac patch technology is still emerging, commercialization 
strategies and considerations could change with changes to the product, regulatory process, team 
functioning, and other outside factors impacting commercialization in the near future. All in all, 
the project team was able to provide next steps for the cardiac patch development team in order 
to have the highest probability of success at commercializing the cardiac patch. 
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Chapter 6: Conclusion 
The project team worked with professors from both the Foisie Business School and 
Biomedical Engineering Department at WPI to address the problem of evaluating the 
commercial pathway of emerging cardiac patch technology developed on-campus. The team felt 
that this goal was achieved through the final recommendations provided to the cardiac patch 
development team, with a plan for successful commercialization.  
The project team first had to decompose the problem at hand. Through the use of 
axiomatic design, the project team was able to divide the problem up into three main objectives 
which would lead to commercial success. The team analyzed the target market population, as 
well as projected market growth, to establish the unmet need and healthy competition necessary 
for a proper value proposition to initiate the commercialization process.   
The team then evaluated how to generate income from commercialization. Through 
contact with medical device industry consultants, three go-to-market strategies were options for 
commercializing the cardiac patch, including licensing, acquisition, and start-ups. The project 
team developed a scaling matrix in order to compare and contrast the applicability of the cardiac 
patch technology with each strategy. Based on the project team’s analysis, licensing was rated 
the highest and deemed to be the best option for commercialization at this stage of development.  
 In addition, the project team analyzed costs and benefits of commercializing the cardiac 
patch technology. Patch materials and costs were summarized following contact with the 
development team’s biomedical PhD students. Indirect costs were estimated based on ranges for 
the cost of FDA approval and securing intellectual property rights, as well as demand projections 
for serving the target population of those seeking treatment following a heart attack. The project 
team also established metrics for measuring benefits of the cardiac patch, using various Harvard 
65 
 
Business School cases. These metrics included the decrease in cost from reduced post-heart 
attack complications and increase in patient quality of life from the cardiac patch.  
With these results, the project team had to recommend the best route of 
commercialization to Professor Pins and the cardiac patch development team. In order to do so, 
the team further analyzed the regulatory and intellectual property requirement for 
commercializing a Class III medical device. The team felt strongly that research and results led 
to a licensing agreement being the best go-to-market option for commercialization at the time.  
Therefore, the team recommended that a licensing deal for the cardiac patch technology 
should look for medical device companies with or without established cardiac divisions to be 
licensees, have non-exclusive terms, license the technology globally, be industry-specific, and 
utilize existing medical codes for insurance purposes. The project team felt that these 
considerations would provide for the largest potential royalty earnings, fastest route to helping 
the most amount of patients, and pave the way for future commercialization options with 
intellectual property set for a platform technology.  
Based on the results and recommendations, the project team recommended next steps to 
the development team for the successful commercialization of the emerging cardiac patch 
technology. In order to increase the likelihood of success, the development team must secure 
strong intellectual property and gain FDA approval for the technology. The cardiac patch 
technology should then be introduced to cardiologists and cardiac surgeons to gage interest in the 
technology and make appropriate changes during clinical development. Finally, the development 
team must determine the medical device code for insurance coverage and can then explore 
additional niche markets that benefit from the same technology platform.  
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As a result of the completion of the project goal, the project team felt that a framework 
was established for the cardiac patch development team to use throughout the commercialization 
process. By examining the target population, market growth, potential income generated, costs 
and benefits, and various intellectual property and regulatory considerations, Professor Pins and 
the cardiac patch development team will be able to effectively weigh the advantages and 
disadvantages of each of the commercialization pathway options. Through the use of a number 
of scientific considerations and business tools provided by this MQP, the cardiac patch 
technology will surely be commercialized successfully, for the benefit of an array of stakeholders 
involved in the process.   
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Appendix D: Strengths, Weaknesses, Opportunities, Threats (SWOT) 
 
SWOT Analysis 
Strengths  Weaknesses  
NIH Grant backing the technology Competitive market  
WPI reputation Much more additional research needed 
before interest  
Accredited Engineers Increasing popularity of preventative 
measures to heart health  
Cost effective No definitive timeline for development  
Early development stages of product Medical device sales tax  
Innovative technology U.S. regulatory processes 
Geographic Location (Boston)    
Opportunities Threats 
Substantial predicted market growth   Growing competition in cardiac patches  
Applicability of technology to other products Cybersecurity 
Increasing aging population (demographics) Lack of future funding  
Less stringent international business  "Product commoditization" 
  Freedom to operate  
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Appendix E: Project Timeline & Gantt Chart 
 
Figure 1: Project weeks 1-7  
 
Figure 2: Project weeks 8-14 
 
Figure 3: Project weeks 15-21 
 
